Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis

Journal of Hepatology

Volumn 31, Issue 2, 1999, Pages 256-262

  Van Hoogstraten, Hubert J F ^a   Hansen, Bettina E ^a   Van Buuren, Henk R ^a   Ten Kate, Fiebo J W ^b   Van Berge Henegouwen, Gerard P ^c   Schalm, Solko W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bile acid therapy; Bio chemical variables; Cholestatic liver disease; Clinical events; Prospective study

Indexed keywords

URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BILE FLOW; BILIARY CIRRHOSIS; BILIRUBIN BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0032776363     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80222-0     Document Type: Article

References (29)

1. Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology. 110:1996;1515-1518.
2. Kaplan MM. Primary biliary cirrhosis - a first step in prolonging survival. N Engl J Med. 19:1994;1386-1387.
3. Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med. 330:1994;1342-1347.
4. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 113:1997;884-890.
5. Lim AG, Jazrawi RP, Northfield TC. The ursodeoxycholic acid story in primary biliary cirrhosis. Gut. 37:1995;301-304.
6. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 19:1994;1149-1156.
7. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 106:1994;1284-1290.
8. Leuschner U, Fischer H, Kurtz W, Guldutuna S, Hubner K, Hellstern A, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology. 97:1989;1268-1274.
9. Turner IB, Myszor M, Mitchison HC, Bennett MK, Burt AD, James OF. A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol. 9:1994;162-168.
10. Combes B, Carithers R Jr., Maddrey WC, Lin D, McDonald MF, Wheeler DE, et al. A randomized, double-blind, placebocontrolled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 22:1995;759-766.
11. Leuschner U, Guldutuna S, Imhof M, Hubner K, Benjaminov A, Leuschner M. Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatol. 21:1994;624-633.
12. Bjorkland A, Totterman TH. Is primary biliary cirrhosis an autoimmune disease? Scand J Gastroenterol Suppl. 204:1994;32-39.
13. James SP, Hoofnagle JH, Strober W, Jones EA. NIH conference: primary biliary cirrhosis: a model autoimmune disease. Ann Intern Med. 99:1983;500-512.
14. Mackay IR, Gershwin ME. Primary biliary cirrhosis: considerations on pathogenesis based on identification of the M2 autoantigens. Springer Semin Immunopathol. 12:1990;101-119.
15. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut. 20:1979;137-140.
16. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med. 308:1983;1-7.
17. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 10:1989;1-7.
18. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol. 20:1994;707-713.
19. Kilmurry MR, Heathcote EJ, Cauch-Dudek K, O'Rourke K, Bailey RJ, Blendis LM, et al. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology. 23:1996;1148-1153.
20. Taal BG, Schalm SW, ten Kate FW, Hermans J, Geertzen RG, Feltkamp BE. Clinical diagnosis of primary biliary cirrhosis: a classification based on major and minor criteria. Hepatogastro-enterology. 30:1983;178-182.
21. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 379:1978;103-112.
22. Bonnand A-M, Heathcote EJ, Lindor KD, Poupon RE. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. J Hepatol. 26:(suppl 1):1997;164.
23. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 18:1993;998-1005.
24. Johnson PJ, McFarlane IG, Williams R. Azathioprine for longterm maintenance of remission in autoimmune hepatitis. N Engl J Med. 333:1995;958-963.
25. Poupon R, Chretien Y, Chazouilleres O, Bonnand AM, Poupon RE. Biochemical response to ursodeoxycholic acid (UDCA) predicts progression of primary biliary cirrhosis. [abstract] Hepatology. 26:(suppl):1997;400A.
26. Hoogstraten HJF van, Smet MBM de, Renooij W, Breed JG, Engels LG, Ouden-Muller J.W den, et al. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Aliment Pharmacol Ther. 12:1998;965-971.
27. Lindor KD, Jorgensen R, Therneau TM, Smith C, Mahoney DW, Dickson ER. Comparison of three different doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized controlied trial. [abstract] Hepatology. 26:(suppl):1997;438A.
28. Meeberg PC van de, Wolfhagen FHJ, Berge Henegouwen GP van, Salemans JMJI, Tangerman A, Buuren HR van, et al. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: relation with biliary enrichment and biochemical response. J Hepatol. 25:1996;887-894.
29. Hoogstraten HJF van, Wolfhagen FHJ, Meeberg PC van de, Kuiper H, Nix GAJJ, Becx MCJM, et al. Ursodeoxycholic acid for primary sclerosing cholangitis: results of a 2-year randomized controlled trial evaluating single versus multiple daily doses. J Hepatol. 29:1998;417-423.